天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Welcome to chemicalbook!
Chinese English Japanese Germany Korea
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook CAS DataBase List Lapatinib
231277-92-2

Lapatinib synthesis

4synthesis methods
Lapatinib is a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.
Synthetic Routes
  • ROUTE 1
  • 202112076948894739.jpg

    Zhang, Yaling; Zhang, Ying; Liu, Juan; Chen, Li; Zhao, Lijun; Li, Baolin; Wang, Wei. Synthesis and in vitro biological evaluation of novel quinazoline derivatives. Bioorganic & Medicinal Chemistry Letters. Volume 27. Issue 7. Pages 1584-1587. 2017

  • ROUTE 2
  • 202112078151021095.jpg

    Petrov, Kimberly G.; Zhang, Yue-Mei; Carter, Malcolm; Cockerill, G. Stuart; Dickerson, Scott; Gauthier, Cassandra A.; Guo, Yu; Mook, Robert A.; Rusnak, David W.; Walker, Ann L.; Wood, Edgar R.; Lackey, Karen E. Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series. Bioorganic & Medicinal Chemistry Letters. Volume 16. Issue 17. Pages 4686-4691. 2006.

  • ROUTE 3
  • 202112079418430246.jpg

    Lackey, Karen Elizabeth; Spector, Neil; Wood, Edgar Raymond, III; Xia, Wenle. 4-Quinazolineamine derivative combination with other antineoplastic agent for cancer treatment, and compound preparation. Assignee Glaxo Group Limited, UK. WO 2002056912. (2002).

  • ROUTE 4
  • 202112072347948329.jpg

    Jyothi Prasad, Ramanadham; Adibhatla Kali Satya, Bhujanga Rao; Venkaiah Chowdary, Nannapaneni. A novel process for the preparation of lapatinib and its pharmaceutically acceptable salts. Assignee Natco Pharma Limited, India. WO 2010061400. (2010).

  • ROUTE 5
  • 202112079115710667.jpg

    Li, Hanpu; Li, Jianzhi; Liu, Hai; Chi, Wangzhou; Zhai, Zhijun; Li, Jianxun. Preparation of Lapatinib drug for treating breast cancer. Assignee Shanghai Tianci Biological Valley Engineering Co., Ltd., Peop. Rep. China. CN 106632276. (2017).

  • ROUTE 6
  • 202112074332670772.jpg

    Ma, Wenli; Liu, Hang; Liang, Jianlin. Method for synthesizing lapatinib or its intermediate. Assignee Chengdu Meiruike Biotechnology Co., Ltd., Peop. Rep. China. CN 106432206. (2017).

  • ROUTE 7
  • 202112077438860138.jpg

    Ji, Xing; Wang, Wuwei; Xu, Guanhong; Li, Fei; Yao, Shechun. Synthesis of lapatinib. Zhongguo Yiyao Gongye Zazhi. Volume 40. Issue 11. Pages 801-804. 2009.

  • ROUTE 8
  • 202112079579969434.jpg

    Hong, Hao; Gage, James; Lu, Jiangping; Li, Jiuyuan; Shen, Litao; Zhu, Zili; Wang, Zedong. Preparation method of substituted o-aminocyanobenzene, and application for synthesis of Lapatinib. Assignee Asymchem Laboratories (Tianjin) Co., Ltd., Peop. Rep. China; Asymchem Life Science (Tianjin) Co., Ltd.; Tianjin Asymchem Pharmaceutical Co., Ltd.; Asymchem Laboratories (Fuxin) Co., Ltd.; Asymchem Laboratories (Jilin) Co., Ltd. CN 105646405. (2016).

  • ROUTE 9
  • 202112075296907793.jpg

    Yuan, Jianyong; Guo, Qing; Li, Yanwu. A process for preparing lapatinib and its intermediates. Assignee Chongqing University of Medical Sciences, Peop. Rep. China. CN 105085496. (2015).

  • ROUTE 10
  • 202112075336383513.jpg

    Reddy, Muddasani Pulla; Rao, Talasila Sambasiva; Reddy, Satti Venkata; Chowdary, Nekkanti Satish; Chowdhary, Nannapaneni Venkaiah. Process for the preparation of lapatinib. Assignee Natco Pharma Limited, India. IN 2013CH01542. (2014).

202112076948894739.jpg

Zhang, Yaling; Zhang, Ying; Liu, Juan; Chen, Li; Zhao, Lijun; Li, Baolin; Wang, Wei. Synthesis and in vitro biological evaluation of novel quinazoline derivatives. Bioorganic & Medicinal Chemistry Letters. Volume 27. Issue 7. Pages 1584-1587. 2017

-

Yield:-

Reaction Conditions:

Stage #1: N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylimino)methyl)furan-2-yl)quinazolin-4-aminewith methanol;sodium tetrahydroborate in tetrahydrofuran at 0 - 15;
Stage #2: with water in tetrahydrofuran;

Steps:

2.v

(v) Preparation of N{3-chloro-4-[(3-fluorobenzyIoxy]phenyl}-6-[5-({[2- methanesuIphonyl)ethyl]amino}methyl)-2-furyI]-4-quinazolinamine (or) Lapatinib base (1)Into a two liter four-necked round bottomed flask, 40OmL of tetrahydrofuran, 40 g of imine obtained from the previous step-(iv), 400 ml of methanol were charged under stirring. The reaction mass was cooled to 0 to 5° C and 7.0 g of sodium borohydride was added in lots and the reaction mass was maintained for about 4 hrs at 10 to 15 0C. The completion of the reaction was monitored by HPLC. To this reaction mass 800 ml of water was added and the product was extracted into ethylacetate. The organic layer was separated and the solvent distilled off completely under vacuum. The solvent was distilled off completely under vacuum. The residue was cooled to 25-35°C and 80 mL of ethylacetate was added, stirred for 2 hrs, filtered and dried under vacuum at 40-450C to get 30.5 g (75% on theory) of crude Lapatinib base. Purity : 90% by HPLC The purity of the above product was enhanced by adopting the following procedure. Purification:Into a two liter four-necked round-bottomed flask, 120OmL of methanol, 30.0 g of Lapatinib crude base obtained as above were charged under stirring. The mass was maintained at 60- 65° C for 30-45 minutes and filtered the undissolved material. The filtrate was distilled off completely under vacuum. The mass was cooled to 25-350C. To the residue 60 mL of methanol was added, stirred for 2 hrs, filtered and dried the product under vacuum at 40-450C to get 28 g of pure Lapatinib base. Purity: 99.5% by HPLC Melting point range: 95-98° C (Peak maximum by DSC) IR (KBr, cm"1): 3485.8, 3303.7, 3060.2, 2924.4, 2814.6, 1921.8, 1592.3, 1573.6, 1525.8, 1490.4, 1457.4, 1422.1, 1385.8, 1365.8, 1337.8, 1319.3, 1288.9, 1268.0, 1215.5, 1133.7, 1060.6, 1029.9, 941.1, 849.3, 779.3, 747.2, 682.0, 552.1, 520.3, 477.7. 2Θ values by XRPD: 11.17, 11.59, 12.30, 12.80, 14.84, 16.15, 16.52, 17.71, 18.88, 20.89, 21.63, 22.37, 22.77, 23.17, 23.80, 24.91, 25.68, 26.61, 28.07, 29.39, 29.87, 30.60, 31.35, 32.29, 34.42, 36.77, 39.41, and 41.31.

References:

WO2010/61400,2010,A1 Location in patent:Page/Page column 16-17

1334953-75-1 Synthesis
N-((5-(4-chloroquinazolin-6-yl)furan-2-yl)Methyl)-2-(Methylsulfonyl)ethanaMine

1334953-75-1
13 suppliers
inquiry

202197-26-0 Synthesis
3-Chloro-4-(3-fluorobenzyloxy)aniline

202197-26-0
300 suppliers
$6.00/1g

Lapatinib Related Search: